KYMR Kymera Therapeutics Inc.

53.79
-2.47  -4%
Previous Close 56.26
Open 55.65
52 Week Low 29.9255
52 Week High 91.92
Market Cap $2,764,114,045
Shares 51,387,136
Float 40,768,757
Enterprise Value $2,373,096,271
Volume 170,328
Av. Daily Volume 294,545
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
KT-474
Hidradenitis suppurativa / atopic dermatitis
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
KT-413
Diffuse large B-cell lymphoma (DLBCL)
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
KT-333
Solid tumors
Phase 1
Phase 1
Phase 1 trial to be initiated 4Q 2021.

Latest News

  1. WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET.

    Kymera's R&D Day will include presentations from Nello Mainolfi, PhD, Co-Founder, President and CEO; Jared Gollob, MD, Chief Medical Officer; and other members of Kymera's senior R&D management team. The event will provide a comprehensive update on Kymera's lead programs and discovery pipeline and platform, including

    • Key Multiple Ascending Dose (MAD) data…

    WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced it will host a virtual R&D Day for analysts and investors that will be held on Thursday, December 16th from 8:30 a.m. to 11:00 a.m. ET.

    Kymera's R&D Day will include presentations from Nello Mainolfi, PhD, Co-Founder, President and CEO; Jared Gollob, MD, Chief Medical Officer; and other members of Kymera's senior R&D management team. The event will provide a comprehensive update on Kymera's lead programs and discovery pipeline and platform, including

    • Key Multiple Ascending Dose (MAD) data from the KT-474 Phase 1 trial
    • Updates on IRAKIMiD (KT-413) and STAT3 (KT-333) programs
    • Presentations on new pathways/programs approaching clinical development
    • Deep-dive into platform capabilities, progress and its expansion
    • Outline of the company's vision and goals for the next 5 years

    A live webcast of the event, as well as a replay, will be available at: https://investors.kymeratx.com/RD-Day

    About Kymera Therapeutics

    Kymera Therapeutics (NASDAQ:KMYR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a global, fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work." For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended September 30, 2021, filed on November 10, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Investor Contact:

    Bruce Jacobs

    Chief Financial Officer



    857-285-5300

    Chris Brinzey

    Managing Director, Westwicke



    339-970-2843

    Media Contact:

    Tyler Gagnon

    Director, Corporate Communications



    508-904-9446



    Primary Logo

    View Full Article Hide Full Article
  2. WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually.

    The results reveal Kymera's potent and selective STAT3 degraders exhibited anti-tumor activity in multiple preclinical animal models of solid and hematologic malignancies that respond poorly to immunotherapies. Administration of a tool STAT3 degrader, KTX-201, led to molecular and cellular…

    WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually.

    The results reveal Kymera's potent and selective STAT3 degraders exhibited anti-tumor activity in multiple preclinical animal models of solid and hematologic malignancies that respond poorly to immunotherapies. Administration of a tool STAT3 degrader, KTX-201, led to molecular and cellular changes in the tumor microenvironment that were predictive of favorable responses to checkpoint inhibition. Consistent with these findings, KTX-201 sensitized these tumors to anti-PD1 treatment when administered in combination, leading to durable anti-tumor responses and development of long-term immunological memory.

    "These encouraging findings underscore the potential power of targeted protein degradation (TPD) to address a range of cancers driven by STAT3, an undruggable transcription factor with effects on both tumor cells and the tumor microenvironment," said Jared Gollob, MD, Chief Medical Officer at Kymera Therapeutics. "We believe our novel data offer critical insights into the antitumor activity of Kymera's STAT3 degraders, particularly their potential to synergize with immunotherapies such as checkpoint blockade – which only work in a small percentage of patients – thereby providing a rationale for selectively degrading STAT3 to sensitize cancers to immune checkpoint inhibition in the clinic."

    STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via Janus kinases (JAKs), as well as through oncogenic fusion proteins and mutations in STAT3 itself. Long considered an "undruggable" target, STAT3 hyperactivation is prominent in numerous liquid and solid tumors, including clinically aggressive lymphomas. Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. Kymera's STAT3 degraders have previously demonstrated strong anti-tumor effects in mouse xenograft and syngeneic models of liquid and solid cancers.

    "Research presented to date on Kymera's STAT3 degraders has bolstered our knowledge of the mechanisms underlying the anti-tumor and immunomodulatory effects associated with STAT3 degradation," said Nello Mainolfi, PhD, Co-Founder, President and CEO, Kymera Therapeutics. "We are eager to advance KT-333, a first-in-class selective STAT3 degrader for liquid and solid tumors into Phase 1 clinical trials by the end of 2021."

    Additional Research Highlights:

    • Treatment of CT-26 (colorectal cancer) and A20 (B-cell lymphoma) tumor-bearing mice with a STAT3 degrader resulted in significant tumor growth inhibition compared to controls, with loss of STAT3 protein in both tumor cells and TME.
    • Treatment of CT-26 and A20 tumor-bearing mice with a STAT3 degrader led to a decrease in M2 polarized macrophages and concomitant increases in M1 polarized macrophages and tumor infiltrating lymphocytes.
    • Gene expression profiling of STAT3 degrader-treated CT-26 tumors showed marked increases in proinflammatory genes including T cell and M1 macrophage activation markers, compared to controls.
    • Induction of an Ifnγ-responsive gene signature (Ifnγ, Stat1, Cxcl9, Cxcl10, Ido1) in CT-26 tumors showed that STAT3 degradation results in a T cell inflamed phenotype associated with responsiveness to immune checkpoint therapy.
      • On-treatment tumors showed an upregulation of genes such as Pdl1, Ctla4, Lag3 which reflect T cell activation as well as counterregulatory mechanisms.
    • STAT3 degradation in combination with anti-PD1 resulted in robust synergy in the CT-26 model with 60% complete responses and development of immunological memory as confirmed by tumor rechallenge studies.
    • Studies are underway to ascertain the applicability of this combination therapy in different tumor immune contextures, and to elucidate the mechanistic basis of synergy.

    Presentation at SITC Annual Meeting:

    • Title: Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Therapy
      • Abstract Number: 603
      • Session Time: 7:00 a.m. – 8:30 a.m. ET on Friday, Nov. 12, 2021
      • Location: Poster Hall (Hall E), Walter E. Washington Convention Center, Washington, D.C.
      • Presenter: Joyoti Dey, Associate Director, Translational Medicine, Kymera Therapeutics

    About Kymera Therapeutics

    Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

    Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work." For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the STAT3 degrader program; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended September 30, 2021, filed on November 10, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Investor Contact:

    Bruce Jacobs

    Chief Financial Officer



    857-285-5300

    Chris Brinzey

    Managing Director, Westwicke



    339-970-2843

    Media Contact:

    Tyler Gagnon

    Director, Corporate Communications



    508-904-9446



    Primary Logo

    View Full Article Hide Full Article
  3. Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines

    FDA clearance of Investigational New Drug Application for first-in-class STAT3 degrader, KT-333

    R&D Day Webinar scheduled for December 16, 2021, with first disclosures of KT-474 Multiple Ascending Dose data, new degrader programs in development and new platform expansions

    WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines…

    Proof-of-mechanism and proof-of-biology established for first-in-class, oral IRAK4 degrader, KT-474, in Single Ascending Dose portion of Phase 1 healthy volunteer trial with up to 96% degradation in blood and up to 97% inhibition of cytokines

    FDA clearance of Investigational New Drug Application for first-in-class STAT3 degrader, KT-333



    R&D Day Webinar scheduled for December 16, 2021, with first disclosures of KT-474 Multiple Ascending Dose data, new degrader programs in development and new platform expansions

    WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the third quarter ended September 30, 2021.

    The company recently reported at the Targeted Protein Degradation (TPD) Summit on October 27th the single ascending dose (SAD) data following completion of dose escalation from the healthy volunteer study of Kymera's first-in-class, oral IRAK4 degrader, KT-474. The study demonstrated up to 96% degradation of IRAK4 in vivo in peripheral blood mononuclear cells (PBMC) and up to 97% inhibition of multiple disease relevant proinflammatory cytokines. The compound continues to demonstrate a favorable safety profile.

    Additionally, the company today announced clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its first-in-class STAT3 degrader, KT-333, now poised to enter the clinic in patients with liquid and solid tumors before year end.

    Kymera announced that the company will be hosting a virtual R&D Day on December 16, 2021. This R&D Day will provide new, key data from the healthy volunteer Multiple Ascending Dose (MAD) portion of the KT-474 Phase 1 trial as well as updates on Kymera's IRAKIMiD (KT-413) and STAT3 (KT-333) programs. The company will also showcase platform expansions, emerging pipeline programs in development as well as Kymera's vision, goals and plans for the next 5 years.

    "We continue to execute and meet important milestones across our pipeline, including our recent data read-out demonstrating proof-of-mechanism and proof-of-biology in humans through the Single Ascending Dose (SAD) portion of our healthy volunteer Phase 1 study for our lead degrader program, KT-474. We believe these data underscore the potential for this drug to be a best-in-class anti-inflammatory agent as well as further validate our targeted protein degradation platform. We look forward to initiating our KT-333 Phase 1 study in patients with liquid and solid tumors now that the FDA has cleared our IND," said Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics. "It is important to highlight that our STAT3 degrader, KT-333, is the first heterobifunctional degrader against an undrugged transcription factor to enter the clinic, another key "first" from the Kymera team this year. This milestone is on the heels of KT-474, which is in the midst of the first placebo-controlled, healthy volunteers Phase 1 study for a targeted protein degrader. We are also very excited to advance our KT-413 IRAKIMiD program towards the clinic and host our first R&D Day event in December, which will showcase the progress we have made and the vision, goals and plans to continue to build Kymera into a fully integrated, best-in-class global targeted protein degradation company."

    Program Updates and Milestones

    Kymera is discovering and developing novel small molecule therapeutics designed to selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, with an initial focus on immune-inflammatory diseases and oncology.

    IRAK4 Degrader Program

    IRAK4 is a key protein involved in inflammation mediated by the activation of toll-like receptors (TLRs) and IL-1 receptors (IL-1Rs). Aberrant activation of these pathways is the underlying cause of multiple immune-inflammatory conditions. KT-474, a potential first-in-class, orally bioavailable IRAK4 degrader, is being developed for the treatment of TLR/IL-1R-driven immune-inflammatory diseases with high unmet medical need, such as atopic dermatitis, hidradenitis suppurativa, rheumatoid arthritis, and other autoimmune inflammatory indications. KT-474 is designed to block TLR/IL-1R-mediated inflammation more broadly compared to monoclonal antibodies targeting single cytokines, and to enable pathway inhibition that is superior to IRAK4 kinase inhibitors by abolishing both the kinase and scaffolding functions of IRAK4. Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immuno-oncology fields.

    Recent Updates:

    • In October 2021, Kymera presented new safety, pharmacokinetic (PK) and pharmacodynamic (PD) data, from the Single Ascending Dose (SAD) portion of the KT-474 Phase 1 randomized, placebo-controlled healthy volunteer trial, at the 4th Annual Targeted Protein Degradation Summit. The data demonstrated robust, dose-dependent IRAK4 reduction, maintained for up to 6 days, in peripheral blood mononuclear cells (PBMC) measured by mass spectrometry, resulting in mean IRAK4 reduction from baseline of 93-96% achieved at 48 hours post-dose at the top three dose levels, achieving strong proof-of-mechanism. For the first time, proof-of-biology was also established, with inhibition of ex vivo R848- or LPS-mediated induction of multiple disease-relevant pro-inflammatory cytokines and chemokines in whole blood at doses and exposures associated with mean IRAK4 reduction in PBMC of ≥85% at 24-48 hours post-dose. In Cohort 7, mean maximum cytokine inhibition as great as 97% was observed. KT-474 was also well-tolerated.
    • In July 2021, Kymera initiated dosing of healthy volunteers in the multiple-ascending-dose, or MAD, portion of the Phase 1 trial of KT-474. The MAD portion of the trial is designed to evaluate repeat daily dosing of KT-474 for 14 days, beginning with a dose of 25 mg, in healthy volunteers randomized 9:3 to KT-474 or placebo.

    Expected Milestones:

    • Presentation of data from the MAD portion of the Phase 1 trial in healthy volunteers (R&D Day, 12/16/21)
    • Initiation of the Phase 1 patient cohort, including patients with hidradenitis suppurativa and atopic dermatitis (1Q22)
    • Presentation of Phase 1 data in AD and HS patient cohort (mid-2022)

    IRAKIMiD Degrader Program

    IRAKIMiDs are novel heterobifunctional degraders designed to degrade both IRAK4 and IMiD substrates, including Ikaros and Aiolos, with a single small molecule. IRAKIMiDs synergistically target both the MYD88-NFkB and IRF4-Type 1 interferon pathways to enhance and broaden anti-tumor activity in multiple contexts, such as MYD88-mutant diffuse large B-cell lymphoma (DLBCL). KT-413 is being developed initially for the treatment of relapsed/refractory MYD88-mutant DLBCL, with the potential to expand into other MYD88-mutant indications and IL-1R/NFkB-driven malignancies.

    Expected Milestones:

    • Clearance of KT-413 IND application to allow for subsequent initiation of Phase 1 clinical trial in relapsed/refractory B cell lymphomas, including MYD88-mutant DLBCL (4Q21)
    • Presentation of additional KT-413 preclinical data and indication expansion strategies (4Q21 and 1H22)
    • Establish Phase 1 proof-of-mechanism in patients (2022)

    STAT3 Degrader Program

    Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via Janus kinases (JAKs), as well as through oncogenic fusion proteins and mutations in STAT3 itself. Long considered an "undruggable" target, STAT3 hyperactivation is prominent in numerous liquid and solid tumors, including clinically aggressive lymphomas. Kymera's STAT3 degraders have demonstrated strong and durable anti-tumor effects in mouse xenograft and syngeneic models of liquid and solid tumors.

    Recent Updates:

    • Today, Kymera announced that it received FDA clearance of its IND to evaluate its lead STAT3 degrader candidate, KT-333, in a Phase 1 clinical trial in relapsed/refractory liquid and solid tumors. Kymera expects to commence a Phase 1 clinical trial before year end. KT-333 is the first heterobifunctional degrader against an undrugged transcription factor to enter clinical development.
    • In November 2021, Kymera announced that multiple abstracts were accepted from its STAT3 degrader program at the upcoming Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting and 63rd American Society of Hematology (ASH) Annual Meeting. At SITC, Kymera will present new preclinical data demonstrating the therapeutic potential of its STAT3 degraders for the treatment of solid tumors. In an in vivo mouse model of colorectal cancer (CT-26) that is poorly responsive to anti-PD1 monotherapy, a STAT3 degrader was evaluated in combination with anti-PD1 therapy, demonstrating robust anti-tumor synergy and development of immunological memory. At ASH, Kymera will present new preclinical data demonstrating STAT3 degrader KT-333's potential to be administered intermittently to drive tumor regressions, including in in vivo models of peripheral T-cell lymphomas (PTCL), such as anaplastic large cell lymphoma (ALCL).

    Expected Milestones:

    • Initiation of Phase 1 clinical trial of KT-333 in relapsed/refractory liquid and solid tumors (4Q21)
    • Establish Phase 1 proof-of-mechanism in patients (2022)

    Platform and Discovery Programs

    Kymera is also actively advancing a broad pipeline of preclinical programs across a wide variety of diseases, both internally and in collaboration with existing partners Vertex Pharmaceuticals and Sanofi. The internal programs continue to be focused on undrugged or inadequately drugged nodes within highly validated pathways in immune-inflammatory and oncology indications. Kymera is also developing a new generation of tissue-selective or -restricted degrader medicines with the goal of drugging an entirely new set of protein targets.

    Corporate Update

    In November 2021, the Company appointed Melissa Brody as Vice President, Business Development. Ms. Brody joins Kymera with multiple years of experience in the biotechnology industry advising biopharma companies on strategic transactions including M&A, licensing, and collaborations.

    Upcoming Events

    Kymera plans to host its inaugural R&D Day webinar on Thursday, December 16, 2021, to discuss its lead programs, unveil its new pathway/programs approaching clinical development, provide an expanded view of platform capabilities, as well as outline the Company's vision and goals for the next five years.

    Additional upcoming events include the following:

    • 11/11: Credit Suisse 30th Annual Virtual Healthcare Conference
    • 11/12: Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
    • 11/15: Stifel 2021 Virtual Healthcare Conference
    • 11/16: Guggenheim Healthcare Talks 3rd Annual Neuro/Immunology Day
    • 11/29-30: Piper Sandler 33rd Annual Healthcare Conference
    • 12/1: Evercore ISI 4th Annual HealthCONx Conference
    • 12/11-14: 63rd American Society of Hematology (ASH) Annual Meeting
    • 1/10-1/13: JP Morgan 40th Annual Health Care Conference

    Third Quarter 2021 Financial Results

    Collaboration Revenues: Collaboration revenues were $20.3 million for the third quarter of 2021, compared to $14.5 million for the same period of 2020. Collaboration revenues in 2021 include revenue from our Sanofi and Vertex collaborations.

    Research and Development Expenses: Research and development expenses were $38.3 million for the third quarter of 2021, compared to $15.8 million for the same period of 2020. This increase was primarily due to expenses related to clinical activities for IRAK4, IND-enabling studies for our IRAKIMiD, and STAT3 programs, investments in our platform and exploratory programs, the Vertex collaboration, as well as an increase in occupancy and related costs due to continued growth in the research and development organization. R&D expenses included $3.4 million and $0.7 million of non-cash stock-based compensation expenses for the third quarters of 2021 and 2020, respectively.

    General and Administrative Expenses: General and administrative expenses were $10.7 million for the third quarter of 2021, compared to $6.8 million for the same period of 2020. This increase was primarily due to increases in legal and professional service fees in support of the Company's growth and an increase in personnel, facility, occupancy, and other expenses from an increase in headcount to support growth as a public company. G&A expenses included $4.0 million and $1.6 million of non-cash stock-based compensation expenses for the third quarters of 2021 and 2020, respectively.

    Net Loss: Net loss was $28.6 million for the third quarter of 2021, compared to a net loss of $8.0 million for the same period of 2020.

    Cash and Cash Equivalents: As of September 30, 2021, Kymera had $611.1 million in cash, cash equivalents, and investments. Kymera expects that its cash, cash equivalents, and investments, excluding any future potential milestones from collaborations, will enable the Company to fund its operational plans into 2025 while the Company continues to identify opportunities to accelerate growth and expand its pipeline, technologies, and clinical indications.

    About Kymera Therapeutics

    Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a global, fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work." For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the IRAK4, IRAKIMiD and STAT3 degrader programs; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities; and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Quarterly Report on Form 10-Q for the period ended September 30, 2021, expected to be filed on or about November 10, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Investor Contact:

    Bruce Jacobs

    Chief Financial Officer



    857-285-5300

    Chris Brinzey

    Managing Director, Westwicke



    339-970-2843

    Media Contact:

    Tyler Gagnon

    Director, Corporate Communications



    508-904-9446



    KYMERA THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands)

    (Unaudited)

     September 30, December 31,
     2021 2020
    Assets       
    Cash, cash equivalents and marketable securities$611,078  $458,733 
    Property and equipment, net 12,184   10,841 
    Other assets 19,191   17,601 
    Total assets$642,453  $487,175 
    Liabilities and Stockholders' Equity        
    Deferred revenue$116,173  $170,390 
    Other liabilities 43,145   32,897 
    Total liabilities 159,318   203,287 
    Total stockholders' equity 483,135   283,888 
    Total liabilities and stockholders' equity$642,453  $487,175 



    KYMERA THERAPEUTICS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

    (In thousands, except for share and per share amounts)

    (Unaudited)

     Three Months Ended Nine Months Ended
     September 30, September 30,
     2021 2020 2021 2020
    Collaboration Revenue—from related parties$20,336   14,533  $57,557  $21,249 
                
    Operating expenses:           
    Research and development$38,306  $15,778  $99,488  $41,713 
    General and administrative 10,667   6,838   24,605   13,058 
    Total operating expenses 48,973   22,616   124,093   54,771 
    Loss from operations (28,637)  (8,083)  (66,536)  (33,522)
    Other income (expense):           
    Interest and Other Income 125   125   343   702 
    Interest and Other Expense (70)  (28)  (124)  (88)
    Total other income: 55   97   219   614 
    Net loss$(28,582) $(7,986) $(66,317) $(32,908)
    Deemed dividend from exchange of convertible preferred stock          9,050 
    Net loss attributable to common stockholders$(28,582) $(7,986) $(66,317) $(41,958)
    Net loss per share attributable to common stockholders, basic and diluted$(0.56) $(0.39) $(1.42) $(5.11)
    Weighted average common stocks outstanding, basic and diluted 50,714,846   20,677,392   46,841,636   8,211,003 


    Primary Logo

    View Full Article Hide Full Article
  4. WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually, and at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.

    Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well…

    WATERTOWN, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced that the Company will present new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place from November 10 - 14, 2021 in Washington, D.C. and virtually, and at the 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 – 14, 2021 in Atlanta, GA and virtually.

    Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis. STAT3 is a transcription factor activated through a variety of different cytokine and growth factor receptors via Janus kinases (JAKs), as well as through oncogenic fusion proteins and mutations in STAT3 itself. Long considered an "undruggable" target, STAT3 hyperactivation is prominent in numerous liquid and solid tumors. Kymera's STAT3 degraders have both antiproliferative and proapoptotic effects on tumor cells as well as immunomodulatory effects on tumor cells and the tumor microenvironment, leading to robust anti-tumor activity in mouse xenograft models of STAT3-dependent T cell lymphomas and syngeneic models of solid tumors.

    "We look forward to presenting new preclinical data showing the synergistic activity of STAT3 degraders combined with immune checkpoint inhibitors in syngeneic mouse models of solid tumors, including the mechanistic basis for that synergy," said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. "We will also profile our lead STAT3 degrader, KT-333, which is nearing entry into the clinic in a Phase 1 trial in liquid and solid tumors, and highlight the preclinical activity of STAT3 degraders in STAT3-dependent T cell lymphomas."

    Presentation at SITC Annual Meeting:

    • Title: Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Therapy
      • Abstract Number: 603
      • Session Time: 7:00 a.m. – 8:30 a.m. ET on Friday, Nov. 12, 2021
      • Location: Poster Hall (Hall E), Walter E. Washington Convention Center, Washington, D.C.
      • Presenter: Joyoti Dey, Associate Director, Translational Medicine, Kymera Therapeutics

    Presentations at ASH Annual Meeting:

    • Title: A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
      • Poster Session: 802. Chemical Biology and Experimental Therapeutics: Poster 1
      • Abstract Number: 1865
      • Session Time: 5:30 p.m. – 7:30 p.m. ET on Saturday, Dec. 11, 2021
      • Location: Hall B5, Georgia World Congress Center, Atlanta, GA
      • Presenter: Phillip Liu, Executive Director, Oncology Biology, Kymera Therapeutics
    • Title: Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
      • Oral Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Targets and Therapeutics
      • Session Time: 6:15 p.m. – 7:45 p.m. ET on Monday, Dec. 13, 2021
      • Location: B302-B303, Georgia World Congress Center, Atlanta, GA
      • Presenter: Giorgio Inghirami, MD, Professor of Pathology and Laboratory Medicine, Weill Cornell Medicine

    About Kymera Therapeutics

    Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

    Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work." For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding its: strategy, business plans and objectives for the STAT3 degrader program; and plans and timelines for the clinical development of Kymera Therapeutics' product candidates, including the therapeutic potential and clinical benefits thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the impact of COVID-19 on countries or regions in which we have operations or do business, as well as on the timing and anticipated results of our current preclinical studies and future clinical trials, strategy and future operations; the delay of any current preclinical studies or future clinical trials or the development of Kymera Therapeutics' drug candidates; the risk that the results of current preclinical studies may not be predictive of future results in connection with future clinical trials; Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates; the timing and outcome of the Company's planned interactions with regulatory authorities, and obtaining, maintaining and protecting its intellectual property. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Annual Report on Form 10-Q for the period ended June 30, 2021, filed on August 6, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Kymera Therapeutics' subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Kymera Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Investor Contact:

    Bruce Jacobs

    Chief Financial Officer



    857-285-5300

    Chris Brinzey

    Managing Director, Westwicke



    339-970-2843

    Media Contact:

    Tyler Gagnon

    Director, Corporate Communications



    508-904-9446



    Primary Logo

    View Full Article Hide Full Article
  5. WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences:

    • UBS: Panel discussion: "TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?" on November 1, 2021 at 11:00 a.m. ET.
    • Credit Suisse 30th Annual Virtual Healthcare Conference: Fireside chat on November 11, 2021 at 1:00 p.m. ET.
    • Stifel 2021 Virtual Healthcare Conference: Fireside chat on November 15, 2021 at 8:40 a.m. ET.
    • Guggenheim Healthcare Talks | Idea Forum | 3rd Annual Neuro/Immunology Day:

    WATERTOWN, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences:

    • UBS: Panel discussion: "TPD from Concept to Clinic: What Have We Learned So Far From Clinical Data?" on November 1, 2021 at 11:00 a.m. ET.
    • Credit Suisse 30th Annual Virtual Healthcare Conference: Fireside chat on November 11, 2021 at 1:00 p.m. ET.
    • Stifel 2021 Virtual Healthcare Conference: Fireside chat on November 15, 2021 at 8:40 a.m. ET.
    • Guggenheim Healthcare Talks | Idea Forum | 3rd Annual Neuro/Immunology Day: Fireside chat on November 16, 2021 at 11:00 a.m. ET.
    • Piper Sandler 33rd Annual Healthcare Conference on November 30, 2021: Fireside chat available to conference participants on-demand.
    • Evercore ISI 4th Annual HealthCONx Conference: Fireside chat, time TBD, December 1-2, 2021.

    Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at www.kymeratx.com. Archived webcast replays will be available on the website for approximately 30 days.

    About Kymera Therapeutics

    Kymera Therapeutics (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera's Pegasus™ platform enables the discovery of novel small molecule degraders designed to harness the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera's goal is to be a fully integrated biopharmaceutical company at the forefront of this new class of protein degrader medicines, with a pipeline of novel degrader medicines targeting disease-causing proteins that were previously intractable.

    Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a "Fierce 15" biotechnology company by FierceBiotech and has been recognized by the Boston Business Journal as one of Boston's "Best Places to Work." For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

    Investor Contact:

    Bruce Jacobs

    Chief Financial Officer



    857-285-5300

    Chris Brinzey

    Managing Director, Westwicke



    339-970-2843

    Media Contact:

    Tyler Gagnon

    Director, Corporate Communications



    508-904-9446



    Primary Logo

    View Full Article Hide Full Article
View All Kymera Therapeutics Inc. News